Bell Potter has an unchanged "buy" recommendation on Starpharma, adding a "speculative" risk tag to the biotech/pharmaceuticals company after its VivaGel symptomatic relief of Bacterial Vaginosis (BV) product was granted marketing approval in Europe.
"The symptomatic relief opportunity is being positioned as an OTC (Over the Counter) consumer product. This means that women will not need to see a doctor to get a prescription and will be able to purchase this off-the-shelf in stores.
Loading...
Elise Shaw writes on Markets specialising in Equity Markets, Commodities, Mining. Based in our Sydney newsroom, Elise has over 25 years experience as a finance and markets journalist and editor. Connect with Elise on Twitter.
